MYLAN-LETROZOLE TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
19-12-2014
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
LETROZOLE
から入手可能:
MYLAN PHARMACEUTICALS ULC
ATCコード:
L02BG04
INN（国際名）:
LETROZOLE
投薬量:
2.5MG
医薬品形態:
TABLET
構図:
LETROZOLE 2.5MG
投与経路:
ORAL
パッケージ内のユニット:
30/100
処方タイプ:
Prescription
治療領域:
ANTINEOPLASTIC AGENTS
製品概要:
Active ingredient group (AIG) number: 0132937001; AHFS:
認証ステータス:
CANCELLED PRE MARKET
承認日:
2016-11-02
製品の特徴
Page 1 of 63 PRODUCT MONOGRAPH
PR
MYLAN-LETROZOLE
letrozole tablets
2.5 mg
USP
Non-steroidal aromatase inhibitor; inhibitor of estrogen biosynthesis;
anti-tumour agent
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Revision:
December 16, 2014
Submission Control No.: 179644
Page 2 of 63
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................................
3
CONTRAINDICATIONS
....................................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................................
4
ADVERSE REACTIONS
...................................................................................................................
10
DRUG INTERACTIONS
.....................................................................................................................
26
DOSAGE AND ADMINISTRATION
..............................................................................................
27
OVERDOSAGE
..................................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................
29
STORAGE AND STABILITY
..........................................................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................... 31
PART II: SCIENTIFIC INFORMATION ........................................................................................
33
PHARMACEUTICAL INFORMATION
............................................................
完全なドキュメントを読む
